Document is current
Any future updates will be listed below
-
Authors
Amin, Najaf https://orcid.org/0000-0002-8944-1771
Liu, Jun https://orcid.org/0000-0001-5288-3042
Sproviero, William
Arnold, Matthias https://orcid.org/0000-0002-4666-0923
Batra, Richa
Bonnechere, Bruno https://orcid.org/0000-0002-7729-4700
Chiou, Yu-Jie https://orcid.org/0000-0003-4543-4075
Fernandes, Marco
Krumsiek, Jan https://orcid.org/0000-0003-4734-3791
Newby, Danielle
Nho, Kwangsik
Kim, Jun Pyo
Saykin, Andrew J. https://orcid.org/0000-0002-1376-8532
Shi, Liu
Winchester, Laura M. https://orcid.org/0000-0003-3826-7694
Yang, Yang https://orcid.org/0000-0001-5720-773X
Nevado-Holgado, Alejo J.
Kastenmüller, Gabi
Kaddurah-Daouk, Rima https://orcid.org/0000-0003-1858-5732
van Duijn, Cornelia M. https://orcid.org/0000-0002-2374-9204
- License Information
-
More Information
Article History
Received: 25 September 2024
Revised: 7 August 2025
Accepted: 2 September 2025
First Online: 31 October 2025
Competing interests
: Dr. Kaddurah-Daouk is an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix. Dr. Arnold is a co-inventor on patents on applications of metabolomics in diseases of the central nervous system and holds equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression. Jan Krumsiek holds equity in iollo, Chymia LLC and IP in PsyProtix. Dr. Saykin has received in-kind support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (PET tracer precursor) and Gates Ventures, LLC and Sanofi (Proteomics panel assays on IADRC and KBASE participants as part of the Global Neurodegeneration Proteomics Consortium) and gift funds (GV) supporting technical contributions to the GRIP platform. and he has participated in Scientific Advisory Boards (Bayer Oncology, Eisai, Novo Nordisk, and Siemens Medical Solutions USA, Inc) and an Observational Study Monitoring Board (MESA, NIH NHLBI), as well as External Advisory Committees for multiple NIA grants. He also serves as Editor-in-Chief of Brain Imaging and Behavior, a Springer-Nature Journal. Najaf Amin and Cornelia M. van Duijn are funded by Oxford-GSK Institute of Molecular and Computational Medicine (IMCM). Cornelia M van Duijn is currently the Research Director Brain Health of the Health Data Research UK (HDR UK) and the UK Dementia Research Institute (UK DRI), working in partnership with Dementias Platform UK (DPUK). All other authors declare no conflicts of interest.
